WO2003035114A1 - Radiopharmaceutical agent for the treatment of early stage cancer - Google Patents

Radiopharmaceutical agent for the treatment of early stage cancer Download PDF

Info

Publication number
WO2003035114A1
WO2003035114A1 PCT/US2002/033918 US0233918W WO03035114A1 WO 2003035114 A1 WO2003035114 A1 WO 2003035114A1 US 0233918 W US0233918 W US 0233918W WO 03035114 A1 WO03035114 A1 WO 03035114A1
Authority
WO
WIPO (PCT)
Prior art keywords
ligand
chelate
metal
cancer
radioactive
Prior art date
Application number
PCT/US2002/033918
Other languages
French (fr)
Inventor
Garry E. Kiefer
Original Assignee
Dow Global Technologies Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies Inc. filed Critical Dow Global Technologies Inc.
Priority to JP2003537678A priority Critical patent/JP2005507001A/en
Priority to EP02789260A priority patent/EP1438076B1/en
Priority to DE60212424T priority patent/DE60212424T2/en
Publication of WO2003035114A1 publication Critical patent/WO2003035114A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Definitions

  • This invention concerns a method of treating cancer in mammals with metal -ligand complexes, and their formulations. More particularly, this invention concerns a method for treating epithelial cancer.
  • Metal ligand complexes are routinely used for medicinal applications. When radioactive metal ions are used, diagnostic imaging or therapy can be the end objective. Thus 99m Tc, a pure gamma emitter, in the form of a metal ligand complex is routinely used as a diagnostic agent. In some cases, such as the use of 99m ⁇ c- DTPA, injection of the complex into the bloodstream does not result in the radionuclide localizing in any tissue. Instead, the radionuclide is eliminated from the body by the kidneys into the urine. In other cases, the radionuclide does localize in desired specific organs or tissues.
  • Bifunctional chelating agents were developed to bind the metal ions to the monoclonal antibody through a chelating agent (which metal - ligand- antibody system is termed a "conjugate”) and many such conjugates have emerged.
  • a chelating agent which metal - ligand- antibody system is termed a "conjugate”
  • bifunctional the covalent attachment of a small molecule to a large protein or antibody
  • Some conjugates use gamma emitters such as 99m Tc or li:L In for imaging (see, for example, U.S. Patents 4,454,106, 3,994,966, 4,662,420 and 4,479,930); and other proposed conjugates with particle emitters such as 67 Cu [see, for example, J. C.
  • the 153 Sm- HEDTA chelates used a 20 to 1 HEDTA to Sm molar ratio.
  • Tumor uptake was found to be significantly less than that of 67 Ga-citrate; liver dose was much greater than tumor dose. He concluded that "it is unlikely that effective therapy doses of Sm-153 can be delivered to melanoma tumors by these and similar chelates.” He suggested the use of monoclonal antibodies with 153 Sm.
  • R is methyl, ethyl, propyl, butyl or H; and R 3 is F, C1-C4 alkyl, 0(C ⁇ -C alkyl) or Cl; M is a radioactive metal ion; or pharmaceutically- acceptable salts thereof; and (2) a pharmaceutically acceptable carrier.
  • the present invention concerns a pharmaceutical formulation for the therapeutic treatment of a mammal having a disease state comprising: (1) a radioactive chelate of formula (I) or pharmaceutically-acceptable salts thereof; and (2) a pharmaceutically acceptable carrier.
  • the method of this invention is used for the therapeutic treatment of a mammal having a disease state.
  • the disease state will be a soft tissue tumor or cancer such as epithelial cancer or cancer of the lymphatic system.
  • epithelial cancer include cancer of the skin, colon, oral cavity, or cervix.
  • compositions used in the method have a radionuclide or metal complexed with a tetraazamacrocyclic chelating agent.
  • a radionuclide or metal complexed with a tetraazamacrocyclic chelating agent As will be more fully discussed later, the properties of the radionuclide, of the chelating agent and of the complex formed therefrom are important considerations in determining the effectiveness of any particular composition employed for such treatment.
  • tumor shall denote a neoplasm, a new abnormal growth of tissue that is not inflammatory, which arises without obvious cause from cells of preexistent tissue, and generally possesses no physiologic function.
  • examples may include "carcinomas” which originate from epithelial cell,
  • sarcomas of mesodermal (connective tissue) origin, and lymphomas from the lymphatic system.
  • the origin of the neoplasm is not critical this invention.
  • complex refers to a chelating agent complexed with a metal ion, preferably a +3 metal ion, especially a radioactive rare- earth type metal ion, wherein at least one metal atom is chelated or sequestered; "radioactive” when used in conjunction with the word “metal ion” refers to one or more isotopes of the rare-earth type elements that emit particles and/or photons.
  • radioactiveuclide or “metal” indicates the metal ion. When the ligand to metal ratio is discussed, the ratio is molar.
  • the metal ligand complexes of this invention can consist of a formulation having the combination of 1 metal with 1 ligand in the form of a complex and having one or more complexes comprised of a different metal and/or different ligand, present in the same formulation.
  • An example of this would be combining one metal ion that is gamma emitting radionuclide for imaging with a ligand and also having present another metal that is a particle emitter for the therapy with the same or different ligand.
  • the combination of radionuclides may be more efficacious than either radionuclide alone.
  • These combinations of complexes may be prepared by administrating two complexes at about the same time to the mammal, or making each complex separately and mixing them prior to use, or mixing the two metal ions with the same ligand and preparing the two or more complexes concurrently.
  • the radionuclide used in the complex of the present invention may be suitable for therapeutic purposes.
  • examples of the radionuclide used for therapeutic purposes are 166 Ho, 165 Dy, 90 Y, 115m In, 52 Fe, or 72 Ga, 225 Ac preferably 166 Ho, 90 Y, 153 Sm, 177 Lu, 175 Yb, 159 Gd, or 47 Sc.
  • Radionuclides can be produced in several ways.
  • a nuclide is bombarded with neutrons to obtain a radionuclide, for example,
  • radionuclides Sm-152 + neutron 7 Sm-153 + gamma
  • Another method of obtaining radionuclides is by bombarding nuclides with linear accelerator or cyclotron- produced particles.
  • Yet another way of obtaining radionuclides is to isolate them from fission product mixtures. The method of obtaining the radionuclide is not critical to the present invention.
  • the desired amount of target is first weighed into a quartz vial, the vial is flame sealed under vacuum and welded into aluminum can. The can is irradiated for the desired length of time, cooled for several hours and opened remotely in a hot cell. The quartz vial is removed and transferred to a glove box, crushed into a glass vial which is then sealed with a rubber septum and an aluminum crimp cap. One milliliter of 1-4 M HC1 is then added to the vial via syringe to dissolve the Sm 2 0 3 . Once dissolved, the solution is diluted to the appropriate volume by addition of water.
  • the solution is removed from the original dissolution vial which contains shards of the crushed quartz vial and transferred via syringe to a clean glass serum vial. This solution is then used for complex preparation. Similar procedures are used to prepare 177 Lu, 159 Gd, and 166 Ho. All radionuclides for this invention are either available commercially or are available from the reactor at the University of Missouri at Columbia.
  • a complex between the metal ion and the ligand can be formed as shown by the equation below.
  • OH- concentration in solution which is related to pH is, therefore, an important parameter to be considered. If the pH is too high, the metal tends to form metal hydroxides rather than complexes.
  • the complexing agents may also be adversely affected by low pH. Complexation may require the loss of proton(s); therefore at low pH, conditions may not be favorable for complexation to occur. Consideration must be given to the solubility characteristics of the ligand, radionuclide, and complex. Although not limited thereto, a pH in the range of from 5 to 11 is preferred for complexation.
  • the chelating agent, or ligand is a tetraazamacrocyclic compound having the formula:
  • R 2 is methyl, ethyl, propyl, butyl or H
  • R 3 is F, C1-C4 alkyl, 0(C 1 -C alkyl) or Cl; or a pharmaceutically acceptable salt thereof.
  • Physiologically acceptable salts refer to the acid addition salts of those bases which will form a salt with at least one acid group of the ligand employed and which will not cause a significant adverse physiological effect when administered to a mammal at dosages consistent with good pharmacological practice.
  • Suitable bases include, for example, the alkali metal and alkaline earth metal hydroxides, carbonates, and bicarbonates such as sodium hydroxide, potassium hydroxide, calcium hydroxide, potassium carbonate, sodium bicarbonate, magnesium carbonate, ammonia, primary, and secondary and tertiary amines.
  • Physiologically acceptable salts may be prepared by treating the acid with an appropriate base.
  • the metal and ligand may be combined under any conditions which allow the two to form a complex.
  • the complexes employed in this invention were prepared as follows: the desired amount of ligand was placed in a vial and dissolved by addition of water. The appropriate amount of the samarium, or other radionuclide, in the stock solution described above was then added to the ligand solution. The pH of the resulting solution was then adjusted to the appropriate level (usually 7-8). Additionally, the complex used in this invention may be a mixture of the different metals as described under the complex term before.
  • the ligand to metal ratio (L:M) of the ligand to radionuclide or metal is at least 50:1.
  • the upper limit of L:M depends on the toxicity of the ligand or the specific activity of the radionuclide.
  • the preferred range for the L:M ratio is from 50:1 to 600:1, preferably from 100:1 to 500:1, especially 250:1 to 300:1.
  • the upper L:M range could be significantly higher, such as 5X10 7 :1.
  • salts means any salt of the ligand which is sufficiently non- toxic to be useful in therapy or diagnosis of mammals.
  • the salts are useful in accordance with this invention.
  • Representative of those salts, which are formed by standard reactions, from both organic and inorganic sources include, for example, sulfuric, hydrochloric, phosphoric, acetic, succinic, citric, lactic, maleic, fumaric, palmitic, cholic, palmoic, mucic, glutamic, d-camphoric, glutaric, glycolic, phthalic, tartaric, formic, lauric, steric, salicylic, methanesulfonic, benzenesulfonic, sorbic, picric, benzoic, cinnamic acids and other suitable acids.
  • salts formed by standard reactions from both organic and inorganic sources such as ammonium, alkali metal ions, alkaline earth metal ions, and other similar ions.
  • Particularly preferred are the salts of the compounds of formula (I) where the salt is calcium, magnesium, potassium, sodium, ammonium, or mixtures thereof .
  • the formulations of the present invention are in the solid or liquid form containing the active radionuclide complexed with the ligand. These formulations may be in kit form such that the two components (that is, ligand and metal) are mixed at the appropriate time prior to use. Whether premixed or as kit, the formulations usually require a pharmaceutically acceptable carrier.
  • compositions of the present invention may be either in suspension or solution form.
  • suitable formulations it will be recognized that, in general, the water solubility of the salt is greater than the acid form.
  • the complex (or when desired the separate components) is dissolved in a physiologically acceptable carrier.
  • suitable solvent include, for example, water, aqueous alcohols, glycols, and phosphate or carbonate esters. Such aqueous solutions contain no more than 50 percent of the organic solvent by volume.
  • Injectable suspensions are compositions of the present invention that require a liquid suspending medium, with or without adjuvants, as a carrier.
  • the suspending medium can be, for example, aqueous polyvinylpyrrolidone, inert oils such as vegetable oils or highly refined mineral oils, or aqueous carboxymethylcellulose.
  • Suitable physiologically acceptable adjuvants, if necessary to keep the complex in suspension may be chosen from among thickeners such as carboxymethylcellulose, polyvinylpyrrolidone, gelatin, and the alginates.
  • surfactants are also useful as suspending agents, for example, lecithin, alkylphenol, polyethylene oxide adducts, napthalenesulfonates, alkylbenzenesulfonates, and the olyoxyethylene sorbitan esters.
  • silicone antifoams are all useful suspending agents.
  • an “effective amount” of the formulation is used for therapy.
  • the dose will vary depending on the disease being treated.
  • the invention described herein provides a means of delivering a therapeutic amount of radioactivity to soft tissue tumors.
  • Therapeutic doses will be administered in sufficient amounts to reduce pain and/or inhibit tumor growth and/or cause regression of tumors and/or kill the tumor. Amounts of radionuclide needed to provide the desired therapeutic dose will be determined experimentally and optimized for each particular composition. The amount of radioactivity required to deliver a therapeutic dose will vary with the individual composition employed.
  • the composition to be administered may be given in a single treatment or fractionated into several portions and composition in fractionated doses may make it possible to minimize damage to non- target tissue. Such multiple dose administration may be more effective.
  • compositions of the present invention may be used in conjunction with other active agents and/or ingredients that enhance the therapeutic effectiveness of the compositions and/or facilitate easier administration of the compositions.
  • the present invention provides a complex which allows metal ions to locate in the tumor and displays low uptake in other tissues, for example, liver.
  • Gd Gadolinium
  • Biodistribution studies were carried out as described above using the corresponding 15-- Sm complexes. Approximately 1 mg/kg of solute was administered to the rat. After 2 hours, the animals were euthanized and their tissues removed, weighed and counted for radioactivity. The total percentage of the dose in bone was calculated by assuming that the bone sample (femur) represents l/25th of the total weight of the skeletal system and distribution is uniform. The total blood dose was calculated by assuming that the blood comprises 6.5 percent of the total body weight. The total muscle dose was calculated by assuming that the muscle comprises 43 percent of the total body weight.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A formulation and method for therapeutic treatment of mammals using certain metals or particle-emitting radionuclides complexed with tetraazamacrocyclic ligands are described.

Description

RADIOPHARMACEUTICAL AGENT FOR THE TREATMENT OF EARLY
STAGE CANCER
This invention concerns a method of treating cancer in mammals with metal -ligand complexes, and their formulations. More particularly, this invention concerns a method for treating epithelial cancer.
Metal ligand complexes are routinely used for medicinal applications. When radioactive metal ions are used, diagnostic imaging or therapy can be the end objective. Thus 99mTc, a pure gamma emitter, in the form of a metal ligand complex is routinely used as a diagnostic agent. In some cases, such as the use of 99mτc- DTPA, injection of the complex into the bloodstream does not result in the radionuclide localizing in any tissue. Instead, the radionuclide is eliminated from the body by the kidneys into the urine. In other cases, the radionuclide does localize in desired specific organs or tissues.
The specific delivery of metals to soft tissue (that is, non-calcific) tumors has been an objective for scientists. Anghilery in Nuklearmedizin 23, 9-14 (1984) describes the difficulty in achieving this objective when he states that "there are no fundamental qualitative differences in the structural, biochemical and functional characteristics of a tumor compared to the normal cell." With the advent of monoclonal antibodies, a plethora of activity has emerged using these proteins to deliver radionuclides to soft tissue tumors [for example, A. R. Fritzberg et al . , Pharm. Res. 5(6), 325 (1988)]. Bifunctional chelating agents were developed to bind the metal ions to the monoclonal antibody through a chelating agent (which metal - ligand- antibody system is termed a "conjugate") and many such conjugates have emerged. Currently, the covalent attachment of a small molecule to a large protein or antibody (referred to as "bifunctional") is receiving much attention as the method of choice for achieving tissue specificity. Some conjugates use gamma emitters such as 99mTc or li:LIn for imaging (see, for example, U.S. Patents 4,454,106, 3,994,966, 4,662,420 and 4,479,930); and other proposed conjugates with particle emitters such as 67Cu [see, for example, J. C. Roberts et al . , Appl .Rad. Isotopes 40 (9), 775 (1989)] or 90Y [see, for example, J.Nucl.Med. 26 (5), 503 (1985)] for therapy. It was believed that the use of the conjugates provided the answer to the site specific delivery of a metal ion to soft tissue tumors. However, in the practice of the use of these conjugates a series of problems has been observed. For example, the problems have involved the fragile nature of the antibody, the slow clearance of the radioactivity from the blood stream, the uptake of radioactivity in non- target tissues such as liver and kidney, and the potential of an immune response of the patient to the injected protein.
One such example of a bifunctional molecule is disclosed in Griffin, J.M.M. et al , "Simple, high yielding synthesis of trifunctional fluorescent lanthanide chelates", Tetrahedron Letters 42 (2001) pp. 1-3. Griffin discloses a lanthanide chelating ligand based on the cyclen (1, 4 , 7 , 10 - tetraazacyclododecane) nucleus which possesses a single carboxyl group for conjugation to a biologically active species such as an antibody. However, this method is inherently complex and expensive since it requires the use of a specialized antibody in order to achieve tissue specificity.
Another approach to delivering metal ions to soft tissue cancers or tumors is by means of a metal ligand complex. Woolfenden et al . in Int. J. Nucl . Med. 10 (4), 251-256 (1983) found that 153Sm-citrate and 153Sm-chloride had a high liver uptake and suggested the use of higher stability chelates, such as 153Sm-EDTA (ethylenediaminetetraacetic acid) , could improve the tumor to liver ratio. More recently, J. Harvey Turner in Eur. J. Nucl. Med. 13, 432-438 (1987) studied 153Sm chelates including HEDTA
(hydroxyethylethylenediaminetriacetic acid) . The 153Sm- HEDTA chelates used a 20 to 1 HEDTA to Sm molar ratio.
Tumor uptake was found to be significantly less than that of 67Ga-citrate; liver dose was much greater than tumor dose. He concluded that "it is unlikely that effective therapy doses of Sm-153 can be delivered to melanoma tumors by these and similar chelates." He suggested the use of monoclonal antibodies with 153Sm.
Another attempt to have complexes deliver metal ions to soft tissue tumors was made by Tsc et al . in J. Nucl. Med. 30, 202-208 (1989) where they studied 153Sm-EDTA at a 10 to 1 ligand to metal molar ratio. These researchers proved that the complex was stable and compared the use of high specific activity 153Sm (1.7 Ci/mG) to low specific activity 153Sm (1.1 mCi/mG) in mice bearing Lewis lung carcinoma. They proposed using the complex as an imaging agent using the high specific activity 153Sm. However, these researchers also found significant uptake in the liver as shown by their biodistribution and images .
Therefore, there is still a need for an adequate system to deliver radionuclides selectively to soft tissue tumors. Surprisingly, it has now been found that various tetraazamacrocyclic complexes give good soft tissue localization and can be used as therapeutic agents .
The present invention concerns a method for the treatment of a disease state in an animal comprised of administering an effective amount of a formulation comprising (1) a radioactive chelate having a formula:
Figure imgf000005_0001
wherein Z is
Figure imgf000005_0002
R is
Figure imgf000005_0003
Figure imgf000006_0001
R is methyl, ethyl, propyl, butyl or H; and R3 is F, C1-C4 alkyl, 0(Cι-C alkyl) or Cl; M is a radioactive metal ion; or pharmaceutically- acceptable salts thereof; and (2) a pharmaceutically acceptable carrier.
In another embodiment, the present invention concerns a pharmaceutical formulation for the therapeutic treatment of a mammal having a disease state comprising: (1) a radioactive chelate of formula (I) or pharmaceutically-acceptable salts thereof; and (2) a pharmaceutically acceptable carrier.
It would be advantageous to use a small molecule therapeutic agent that would localize in a specific tissue of the body without the need for attachment to a delivery molecule such as an antibody.
The method of this invention is used for the therapeutic treatment of a mammal having a disease state. In most embodiments, the disease state will be a soft tissue tumor or cancer such as epithelial cancer or cancer of the lymphatic system. Examples of epithelial cancer include cancer of the skin, colon, oral cavity, or cervix.
The compositions used in the method have a radionuclide or metal complexed with a tetraazamacrocyclic chelating agent. As will be more fully discussed later, the properties of the radionuclide, of the chelating agent and of the complex formed therefrom are important considerations in determining the effectiveness of any particular composition employed for such treatment.
For the purposes of this invention, the term "tumor" shall denote a neoplasm, a new abnormal growth of tissue that is not inflammatory, which arises without obvious cause from cells of preexistent tissue, and generally possesses no physiologic function. Examples may include "carcinomas" which originate from epithelial cell,
"sarcomas" of mesodermal (connective tissue) origin, and lymphomas from the lymphatic system. The origin of the neoplasm is not critical this invention.
As used herein, "complex" refers to a chelating agent complexed with a metal ion, preferably a +3 metal ion, especially a radioactive rare- earth type metal ion, wherein at least one metal atom is chelated or sequestered; "radioactive" when used in conjunction with the word "metal ion" refers to one or more isotopes of the rare-earth type elements that emit particles and/or photons. The term "radionuclide" or "metal" indicates the metal ion. When the ligand to metal ratio is discussed, the ratio is molar. The metal ligand complexes of this invention can consist of a formulation having the combination of 1 metal with 1 ligand in the form of a complex and having one or more complexes comprised of a different metal and/or different ligand, present in the same formulation. An example of this would be combining one metal ion that is gamma emitting radionuclide for imaging with a ligand and also having present another metal that is a particle emitter for the therapy with the same or different ligand. The combination of radionuclides may be more efficacious than either radionuclide alone. These combinations of complexes may be prepared by administrating two complexes at about the same time to the mammal, or making each complex separately and mixing them prior to use, or mixing the two metal ions with the same ligand and preparing the two or more complexes concurrently.
The radionuclide used in the complex of the present invention may be suitable for therapeutic purposes. Examples of the radionuclide used for therapeutic purposes are 166Ho, 165Dy, 90Y, 115mIn, 52Fe, or 72Ga,225Ac preferably 166Ho, 90Y, 153Sm, 177Lu, 175Yb, 159Gd, or 47Sc.
Radionuclides cart be produced in several ways. In a nuclear reactor, a nuclide is bombarded with neutrons to obtain a radionuclide, for example,
Sm-152 + neutron 7 Sm-153 + gamma Another method of obtaining radionuclides is by bombarding nuclides with linear accelerator or cyclotron- produced particles. Yet another way of obtaining radionuclides is to isolate them from fission product mixtures. The method of obtaining the radionuclide is not critical to the present invention.
To irradiate Sm203 for production of Sm-153, the desired amount of target is first weighed into a quartz vial, the vial is flame sealed under vacuum and welded into aluminum can. The can is irradiated for the desired length of time, cooled for several hours and opened remotely in a hot cell. The quartz vial is removed and transferred to a glove box, crushed into a glass vial which is then sealed with a rubber septum and an aluminum crimp cap. One milliliter of 1-4 M HC1 is then added to the vial via syringe to dissolve the Sm203. Once dissolved, the solution is diluted to the appropriate volume by addition of water. The solution is removed from the original dissolution vial which contains shards of the crushed quartz vial and transferred via syringe to a clean glass serum vial. This solution is then used for complex preparation. Similar procedures are used to prepare 177Lu, 159Gd, and 166Ho. All radionuclides for this invention are either available commercially or are available from the reactor at the University of Missouri at Columbia.
When aqueous solutions of metal ions are mixed with solutions containing complexing agents, such as tetraazamacrocyclic compounds, a complex between the metal ion and the ligand can be formed as shown by the equation below.
M + L M -L The reaction is believed to be in equilibrium such that the concentrations of metal (M) and complexing agent, or ligand (L) , can affect the concentration of species present in solution. Competing side reactions, such as metal hydroxide formation, can also occur in aqueous solution, thus
xM + yOH- Mx(OH)y The OH- concentration in solution, which is related to pH is, therefore, an important parameter to be considered. If the pH is too high, the metal tends to form metal hydroxides rather than complexes. The complexing agents may also be adversely affected by low pH. Complexation may require the loss of proton(s); therefore at low pH, conditions may not be favorable for complexation to occur. Consideration must be given to the solubility characteristics of the ligand, radionuclide, and complex. Although not limited thereto, a pH in the range of from 5 to 11 is preferred for complexation.
The chelating agent, or ligand, is a tetraazamacrocyclic compound having the formula:
Figure imgf000010_0001
wherein Z is
Figure imgf000010_0002
Figure imgf000010_0003
Figure imgf000011_0001
R2 is methyl, ethyl, propyl, butyl or H; and
R3 is F, C1-C4 alkyl, 0(C1-C alkyl) or Cl; or a pharmaceutically acceptable salt thereof.
For the purpose of the present invention, the complexes described herein and physiologically acceptable salts thereof are considered equivalent in the therapeutically effective compositions. Physiologically acceptable salts refer to the acid addition salts of those bases which will form a salt with at least one acid group of the ligand employed and which will not cause a significant adverse physiological effect when administered to a mammal at dosages consistent with good pharmacological practice. Suitable bases include, for example, the alkali metal and alkaline earth metal hydroxides, carbonates, and bicarbonates such as sodium hydroxide, potassium hydroxide, calcium hydroxide, potassium carbonate, sodium bicarbonate, magnesium carbonate, ammonia, primary, and secondary and tertiary amines. Physiologically acceptable salts may be prepared by treating the acid with an appropriate base.
The metal and ligand may be combined under any conditions which allow the two to form a complex.
Generally, mixing in water at a controlled pH (the choice of pH is dependent upon the choice of metal) is all that is required. Most of the complexes employed in this invention were prepared as follows: the desired amount of ligand was placed in a vial and dissolved by addition of water. The appropriate amount of the samarium, or other radionuclide, in the stock solution described above was then added to the ligand solution. The pH of the resulting solution was then adjusted to the appropriate level (usually 7-8). Additionally, the complex used in this invention may be a mixture of the different metals as described under the complex term before.
In the method of this invention, it is necessary to employ the complex in the presence of an excess of ligand. The ligand to metal ratio (L:M) of the ligand to radionuclide or metal is at least 50:1. The upper limit of L:M depends on the toxicity of the ligand or the specific activity of the radionuclide. The preferred range for the L:M ratio is from 50:1 to 600:1, preferably from 100:1 to 500:1, especially 250:1 to 300:1.
When the radionuclide is used in the no carrier added form, then the upper L:M range could be significantly higher, such as 5X107:1.
As used herein, the term "mammal" means animals that nourish their young with milk secreted by mammary glands, preferably warm blooded mammals, more preferably humans.
As used herein, "pharmaceutically acceptable salt" means any salt of the ligand which is sufficiently non- toxic to be useful in therapy or diagnosis of mammals. Thus, the salts are useful in accordance with this invention. Representative of those salts, which are formed by standard reactions, from both organic and inorganic sources include, for example, sulfuric, hydrochloric, phosphoric, acetic, succinic, citric, lactic, maleic, fumaric, palmitic, cholic, palmoic, mucic, glutamic, d-camphoric, glutaric, glycolic, phthalic, tartaric, formic, lauric, steric, salicylic, methanesulfonic, benzenesulfonic, sorbic, picric, benzoic, cinnamic acids and other suitable acids. Also included are salts formed by standard reactions from both organic and inorganic sources such as ammonium, alkali metal ions, alkaline earth metal ions, and other similar ions. Particularly preferred are the salts of the compounds of formula (I) where the salt is calcium, magnesium, potassium, sodium, ammonium, or mixtures thereof .
The formulations of the present invention are in the solid or liquid form containing the active radionuclide complexed with the ligand. These formulations may be in kit form such that the two components (that is, ligand and metal) are mixed at the appropriate time prior to use. Whether premixed or as kit, the formulations usually require a pharmaceutically acceptable carrier.
Injectable compositions of the present invention may be either in suspension or solution form. In the preparation of suitable formulations it will be recognized that, in general, the water solubility of the salt is greater than the acid form. In solution form the complex (or when desired the separate components) is dissolved in a physiologically acceptable carrier. Such carriers comprise a suitable solvent, preservatives such as benzyl alcohol, if needed, and/or buffers. Useful solvents include, for example, water, aqueous alcohols, glycols, and phosphate or carbonate esters. Such aqueous solutions contain no more than 50 percent of the organic solvent by volume.
Injectable suspensions are compositions of the present invention that require a liquid suspending medium, with or without adjuvants, as a carrier. The suspending medium can be, for example, aqueous polyvinylpyrrolidone, inert oils such as vegetable oils or highly refined mineral oils, or aqueous carboxymethylcellulose. Suitable physiologically acceptable adjuvants, if necessary to keep the complex in suspension, may be chosen from among thickeners such as carboxymethylcellulose, polyvinylpyrrolidone, gelatin, and the alginates. Many surfactants are also useful as suspending agents, for example, lecithin, alkylphenol, polyethylene oxide adducts, napthalenesulfonates, alkylbenzenesulfonates, and the olyoxyethylene sorbitan esters.
Many substances which affect the hydrophilicity, density, and surface tension of the liquid suspension medium can assist in making injectable suspension in individual cases. For example, silicone antifoams, sorbitol, and sugars are all useful suspending agents.
An "effective amount" of the formulation is used for therapy. The dose will vary depending on the disease being treated. The invention described herein provides a means of delivering a therapeutic amount of radioactivity to soft tissue tumors. However, it may also be desirable to administer a "sub- therapeutic" amount to determine the fate of the radoinuclide using a scintillation camera prior to administering a therapeutic dose or if diagnostic images are the desired result. Therapeutic doses will be administered in sufficient amounts to reduce pain and/or inhibit tumor growth and/or cause regression of tumors and/or kill the tumor. Amounts of radionuclide needed to provide the desired therapeutic dose will be determined experimentally and optimized for each particular composition. The amount of radioactivity required to deliver a therapeutic dose will vary with the individual composition employed. The composition to be administered may be given in a single treatment or fractionated into several portions and composition in fractionated doses may make it possible to minimize damage to non- target tissue. Such multiple dose administration may be more effective.
The compositions of the present invention may be used in conjunction with other active agents and/or ingredients that enhance the therapeutic effectiveness of the compositions and/or facilitate easier administration of the compositions.
While not wishing to be bound by theory, it is believed that the advantageous results of the present invention are obtained because of the possible uptake preferentially in the tumor. The mechanism of uptake of the radionuclide by neoplastic tissue is not clear. Some suggested mechanisms are:
a) An imbalance between arterial blood supply to the tumor and venous drainage from the tumor. A reduced venous drainage would result in an increase in concentration of the material within the tumor mass . b) Lymphatic drainage from a tumor may be decreased. c) Non-specific binding to protein within the tumor may occur. d) Because inflammatory reaction is usually present near a tumor, this may result in the differential concentration of radiolabel within the tumor . e) MetallothionEin a protein binder of heavy metals. f) Several mechanisms may be involved.
Although the theory for the mechanism of action is still unknown, the present invention provides a complex which allows metal ions to locate in the tumor and displays low uptake in other tissues, for example, liver.
The following definitions are provided for some terms that are used throughout this text. Glossary:
Cone. = concentrated mG = milligrams mCi = milliCuries HEDTA = Hydroxyethylethylenediaminetriacetic acid
Ac = Actinium
Sm = Samarium
Ho = Holmium Yb = Ytterbium
Y = Yttrium
Gd = Gadolinium
Lu = Lutetium
In = Indium Sc = Scandium
Fe = iron
Ga = Gallium chelant is equivalent to ligand complex is equivalent to chelate, and L:M = ligand to metal molar ratio.
The invention will be further clarified by a consideration of the following examples, which are intended to be purely exemplary of the present invention,
Biodistribution Studies
Example 1 The details of the tissue biodistribution studies are as follows. A !'7'7LuCl3 solution was prepared as were the appropriate ligand Biodistribution solutions. The two solutions were thoroughly mixed at a pH = 2 and the pH of the solution was raised to 7 using 0. IN NaOH to facilitate complexation. Complexation was then evaluated by passing the sample solution (100 μL) through a Sephadex™ C-25 column eluting (2 x 3 mL) with 4:1 saline (0.85 percent aCl/ H4H) and comparing the amount of radioactivity in the eluent with that remaining on the column (free metal remains on the column) . The in vivo distribution of the radioactive complexes was measured using three Sprague Dawley rats (180-220 g) , each injected with 100 μL (pH = 7.5) of the radioactive complex solution. After 30 minutes or 2 hours, the animals were sacrificed. The organs were removed, weighed and counted. The total percentage of the dose in bone was calculated using the standard assumptions regarding the total body weight percentages. For example, the bone sample (femur) represents 1/25 the weight of the total skeletal system and total muscle dose was calculated by assuming that muscle comprises 43 percent of the total body weight.
Figure imgf000017_0001
Lu-QM(CTPB);R = C4Hg Lu-QM(CTPE) ; R = C 2H5 Lu-QM(CTPH) ; R = H
Butyl - ester -quinolin, Lu- 177 [Lu -QM (CTPB)
10 : 1 , Ligand rMetal Molar Ratio, Ligand = 2 . 0 mM
PERCENT
DOSE
RAT 1 RAT 2 RAT 3 AVERAGE +/-
BONE 10.34 12.32 10.22 10.96 1.18
TAIL 6.43 2.38 8.59 5.80 3.15
LIVER 10.85 11.29 9.62 10.59 0.86
KIDNEY 3.18 3.96 3.39 3.51 0.40
SPLEEN 0.60 0.54 0.67 0.60 0.06
MUSCLE 4.93 4.42 4.47 4.61 0.28
BLOOD 7.11 6.67 6.05 6.61 0.54
HEART 0.10 0.14 0.14 0.13 0.02
LUNG 0.43 0.30 0.74 0.49 0.22
BRAIN 0.02 0.03 0.16 0.07 0.08
STOMACH 0.09 1.32 2.22 1.21 1.07
SMALL INT1 2.28 1.49 40.60 14.79 22.36
SMALL INT2 40.88 43.37 1.70 28.65 23.37
CEACUM 0.59 0.23 0.11 0.31 0.25
COLON 0.10 0.12 0.25 0.16 0.08
TESTES 0.29 0.33 0.19 0.27 0.07
PANCREAS 0.17 0.15 0.00 0.11 0.09
URINE 13.26 10.89 12.51 12.22 1.21
TOTAL ACCOUNTABILITY
RAT 1 RAT 2 RAT 3 AVERAGE +/-
101.67 99.94 101.60 101.07 0.69
DATE LIGAND
1 - 30 - 01 , Ethyl - ester - quinolin, Lu- 177
Lu-QM (CTPE)
10:1, Ligand:Metal Molar Ratio, Ligand = 2.0 mM
RAT 1 RAT 2 +/-
BONE 7.95 9.36 0.87
TAIL 6.49 0.94 2.81
LIVER 2.87 4.29 4.47
KIDNEY 3.98 3.79 0.62
SPLEEN 0.20 1.10 0.56
MUSCLE 3.86 4.31 0.80
BLOOD 4.13 6.37 1.59
HEART 0.12 0.11 0.04
LUNG 0.24 0.49 0.16
BRAIN 0.01 0.00 0.01
STOMACH 0.23 11.76 6.14
SMALL INT1 0.61 0.98 1.64
SMALL INT2 2.76 14.02 5.72
CEACUM 4.02 3.75 2.17
COLON 0.16 0.10 0.04
PANCREAS 0.05 0.07 0.01
URINE 9.60 79.72 35.53 TOTAL ACCOUNTABILITY RAT 1 RAT 2 +/-
47.27 141.17 33.74
DATE LIGAND
1-30-01, Phosphonic acid-quinolin, Lu-177 Lu-QM(CTPH)
10:1, LigandrMetal Molar Ratio, Ligand = 2.0 mM
RAT 1 RAT 2 +/-
BONE 44.87 26.77 9.07
TAIL 2.35 10.86 4.78
LIVER 5.81 3.62 1.68
KIDNEY 2.29 3.12 0.52
SPLEEN 0.49 0.12 0.23
MUSCLE 12.65 10.20 1.23
BLOOD 16.95 12.50 2.31
HEART 0.53 0.32 0.12
LUNG 1.26 0.76 0.37
BRAIN 0.09 0.08 0.02
STOMACH 0.71 6.00 2.75
SMALL I T1 1.21 5.32 2.06
SMALL INT2 1.07 1.89 1.95
CEACUM 0.28 0.17 0.09
COLON 0.20 0.12 0.09
PANCREAS 0.12 0.08 0.09
URINE 16.20 14.00 6.07
TOTAL ACCOUNTABILITY RAT 1 RAT 2 +/-
107.10 95.92 4.69
Example 2
Biodistribution studies were carried out as described above using the corresponding 15-- Sm complexes. Approximately 1 mg/kg of solute was administered to the rat. After 2 hours, the animals were euthanized and their tissues removed, weighed and counted for radioactivity. The total percentage of the dose in bone was calculated by assuming that the bone sample (femur) represents l/25th of the total weight of the skeletal system and distribution is uniform. The total blood dose was calculated by assuming that the blood comprises 6.5 percent of the total body weight. The total muscle dose was calculated by assuming that the muscle comprises 43 percent of the total body weight.
Other embodiments of the invention will be apparent to those skilled in the art from a consideration of this specification or practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with the true scope and spirit of the invention being indicated by the following claims.

Claims

WHAT IS CLAIMED IS:
1. A method for the treatment of a disease state in an animal comprised of administering an effective amount of a formulation comprising a radioactive chelate having a formula:
Figure imgf000021_0001
wherein Z is
Figure imgf000021_0002
R is
Figure imgf000021_0003
Figure imgf000022_0001
R is methyl, ethyl, propyl , butyl or H; and
R is F, C1-C4 alkyl, 0(Cι-C4 alkyl) or Cl; M is a radioactive metal ion; or pharmaceutically-acceptable salts thereof; and a pharmaceutically acceptable carrier.
2. The method of Claim 1 wherein M is Sm, DHo,
165 Dy, Gd, Lu, Lln, 72, 67,
"In, ±,3Yb, "Sc, "Fe, "Ga, "6a, Ga, 225Ac, or Fe.
3. The method of Claim 1 wherein the chelate has a ligand to metal molar ratio of at least 50:1.
The method of claim 1 where the formulation is administered topically or as an injectable solution.
4. The method of claim 4 wherein for topical applications the chelate is formulated at a concentration of 1 •M-10mM in an aqueous solution.
5. The method of claim 4 wherein for injectable application the chelate is administered at 0.001-0.2 mmol/Kg of body weight.
6. The method of claim 1 wherein the disease state is epithelial cancer or cancer of the lymphatic system.
7. The method of claim 7 wherein the epithelial cancer is in the skin, colon, oral cavity, or cervix.
8. A pharmaceutical formulation for the therapeutic treatment of a mammal having a disease state comprising: (1) a radioactive chelate having a formula:
Figure imgf000023_0001
wherein Z is
Figure imgf000023_0002
R is
Figure imgf000023_0003
Figure imgf000024_0001
R is methyl, ethyl, propyl , butyl or H; and R3 is F, C1-C4 alkyl, 0(Cι-C alkyl) or Cl;
M is a radioactive metal ion; or pharmaceutically-acceptable salts thereof; and (2) a pharmaceutically acceptable carrier.
9 . The method of Claim 9 wherein M is 153Sm, 16δHo , 90Y ,
165— D.y, 159G,,d -,, 177τLu, lllτIn, llSm.I_n, 175,Y,,b, 47S _c, 52 -F--e, 72G _,a, 67G _.a, 6βGa, 225Ac, or Fe.
10. The method of Claim 9 wherein the chelate has a ligand to metal molar ratio of at least 50:1.
11. The method of claim 9 where the formulation is administered topically or as an injectable solution.
12. The method of claim 12 wherein for topical applications the chelate is formulated at a concentration of 1 'M-lOrnM in an aqueous solution.
13. The method of claim 12 wherein for injectable application the chelate is administered at 0.001-0.2 mmol/Kg of body weight.
14. The method of claim 9 wherein the disease state is epithelial cancer or cancer of the lymphatic system.
15. The method of claim 15 wherein the epithelial cancer is in the skin, colon, oral cavity, or cervix.
PCT/US2002/033918 2001-10-22 2002-10-22 Radiopharmaceutical agent for the treatment of early stage cancer WO2003035114A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2003537678A JP2005507001A (en) 2001-10-22 2002-10-22 Radiopharmaceuticals for the treatment of early cancer
EP02789260A EP1438076B1 (en) 2001-10-22 2002-10-22 Radiopharmaceutical agent for the treatment of early stage cancer
DE60212424T DE60212424T2 (en) 2001-10-22 2002-10-22 RADIOPHARMACEUTIC AGENT FOR THE TREATMENT OF CANCER IN EARLY STADIUM

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35559801P 2001-10-22 2001-10-22
US60/355,598 2001-10-22

Publications (1)

Publication Number Publication Date
WO2003035114A1 true WO2003035114A1 (en) 2003-05-01

Family

ID=23398047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/033918 WO2003035114A1 (en) 2001-10-22 2002-10-22 Radiopharmaceutical agent for the treatment of early stage cancer

Country Status (6)

Country Link
US (1) US20030133872A1 (en)
EP (1) EP1438076B1 (en)
JP (1) JP2005507001A (en)
AT (1) ATE329623T1 (en)
DE (1) DE60212424T2 (en)
WO (1) WO2003035114A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049096A2 (en) * 2003-11-14 2005-06-02 Dow Global Technologies Inc. Protein and polymer conjugates as chelants with enhanced blood retention

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778699A4 (en) * 2004-08-10 2009-02-25 Dow Global Technologies Inc Targeting chelants and chelates
KR102651945B1 (en) * 2015-07-07 2024-03-26 파이브 일레븐 파마 인크. HBED-bisphosphonate, its radiometal conjugate, and its use as a diagnostic treatment agent

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011801A1 (en) * 1991-12-10 1993-06-24 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes, their preparation, conjugates and radiopharmaceuticals
WO1994003464A1 (en) * 1984-10-18 1994-02-17 Board Of Regents, The University Of Texas System Polyazamacrocyclic compounds for complexation of metal ions
WO1994026753A1 (en) * 1993-05-06 1994-11-24 The Dow Chemical Company Process for the preparation of azamacrocylcic or acyclic aminophosphonate ester derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994996A (en) * 1972-02-11 1976-11-30 Fmc Corporation Polymeric phosphazenes and process for preparation
GB2126278B (en) * 1981-10-05 1986-03-05 Sanwa Shutter Corp Panel shutter device
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4779930A (en) * 1987-09-17 1988-10-25 Rosen Steven B Infant head support for use with infant retaining devices
US5739294A (en) * 1991-12-10 1998-04-14 The Dow Chemical Company Bicyclopol yazamacrocyclophosphonic acid complexes for use as contrast agents
IL126659A (en) * 1996-04-19 2003-05-29 Dow Global Technologies Inc Fluorescent chelates as visual tissue specific imaging agents
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
US7338651B2 (en) * 2001-09-04 2008-03-04 Texas Tech University System Multi-use multimodal imaging chelates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003464A1 (en) * 1984-10-18 1994-02-17 Board Of Regents, The University Of Texas System Polyazamacrocyclic compounds for complexation of metal ions
WO1993011801A1 (en) * 1991-12-10 1993-06-24 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes, their preparation, conjugates and radiopharmaceuticals
WO1994026753A1 (en) * 1993-05-06 1994-11-24 The Dow Chemical Company Process for the preparation of azamacrocylcic or acyclic aminophosphonate ester derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049096A2 (en) * 2003-11-14 2005-06-02 Dow Global Technologies Inc. Protein and polymer conjugates as chelants with enhanced blood retention
WO2005049096A3 (en) * 2003-11-14 2005-12-29 Dow Global Technologies Inc Protein and polymer conjugates as chelants with enhanced blood retention

Also Published As

Publication number Publication date
US20030133872A1 (en) 2003-07-17
ATE329623T1 (en) 2006-07-15
EP1438076A1 (en) 2004-07-21
DE60212424T2 (en) 2006-10-12
JP2005507001A (en) 2005-03-10
EP1438076B1 (en) 2006-06-14
DE60212424D1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
EP0408701B1 (en) Macrocyclic aminophosphonic acid complexes, their preparation, formulations and use
US4897254A (en) Radioactive compositions for the treatment of calcific tumors
JPH02237936A (en) Bone marrow checking agent
US5064633A (en) Macrocyclic aminophosphonic acid complexes, their formulations and use
EP0499098B1 (en) Ligand based pharmaceutical for the treatment and/or diagnose of soft tissue tumors
US6670456B2 (en) Actinium-225 complexes and conjugates for targeted radiotherapy
JPH0448799B2 (en)
Appelbaum et al. Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP
El-Mabhouh et al. Preclinical investigations of drug and radionuclide conjugates of bisphosphonates for the treatment of metastatic bone cancer
EP1438076B1 (en) Radiopharmaceutical agent for the treatment of early stage cancer
WO2001066155A2 (en) Actinium-225 complexes and conjugates for radioimmunotherapy
AU2002353865A1 (en) Radiopharmaceutical agent for the treatment of early stage cancer
EP0497356B1 (en) Compositions and method for soft tissue tumors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002353865

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002789260

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003537678

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002789260

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002789260

Country of ref document: EP